Goldman Sachs
TARA icon

Goldman Sachs’s Protara Therapeutics TARA Stock Holding History

Goldman Sachs’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.09M Buy
546,227
+148,246
+37% +$705K ﹤0.01% 4652
2026
Q1 		$2.07M Buy
397,981
+334,489
+527% +$1.98M ﹤0.01% 4517
2025
Q4 		$338K Buy
63,492
+49,884
+367% +$277K ﹤0.01% 5805
2025
Q3 		$59.2K Sell
13,608
-123,979
-90% -$401K ﹤0.01% 6151
2025
Q2 		$417K Sell
137,587
-61,667
-31% -$213K ﹤0.01% 5260
2025
Q1 		$849K Sell
199,254
-3,971
-2% -$17.7K ﹤0.01% 4817
2024
Q4 		$1.07M Buy
+203,225
New +$657K ﹤0.01% 4773
2022
Q2 		– Sell
-152,847
Closed -$781K – 6711
2022
Q1 		$781K Sell
152,847
-44,455
-23% -$234K ﹤0.01% 5017
2021
Q4 		$1.33M Buy
197,302
+41,329
+26% +$285K ﹤0.01% 4606
2021
Q3 		$1.08M Buy
155,973
+23,716
+18% +$185K ﹤0.01% 4685
2021
Q2 		$1.29M Buy
+132,257
New +$1.5M ﹤0.01% 4570
2020
Q2 		– Sell
-15,299
Closed -$352K – 5472
2020
Q1 		$352K Buy
+15,299
New +$446K ﹤0.01% 4410

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Goldman Sachs's TARA Position: Q2 2026 in Review

Goldman Sachs increased its Protara Therapeutics (TARA) stake by 37% in Q2 2026, buying an estimated $705K and bringing the position to 546,227 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #4652.

Goldman Sachs first reported a position in TARA in Q1 2020 and has held it in 12 quarters since. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Goldman Sachs held 546,227 shares of Protara Therapeutics worth $2.09M as of Q2 2026.
  • Goldman Sachs bought 148,246 Protara Therapeutics shares in Q2 2026, an estimated $705K.
  • Protara Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4652 holding.
  • Goldman Sachs first reported a position in Protara Therapeutics in Q1 2020 and has held it in 12 quarters since.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.